Trials / Completed
CompletedNCT06310005
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Subcutaneous Doses and Multiple Subcutaneous Doses Over 6 Weeks of BI 3006337 in Healthy Male Japanese Subjects (Single-blind, Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BI 3006337 in healthy male subjects following s.c. administration of single rising doses and multiple doses over 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 3006337 | BI 3006337 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-04-19
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2024-03-13
- Last updated
- 2025-12-22
- Results posted
- 2025-12-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06310005. Inclusion in this directory is not an endorsement.